New York University School of Medicine-ko ikertzaileekin lankidetzan egindako argitalpenak (10)

2022

  1. Diagnosis of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors

    JAMA Dermatology

2021

  1. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2019

  1. Assessment of Quality of Life and Treatment Outcomes of Patients with Persistent Postchemotherapy Alopecia

    JAMA Dermatology, Vol. 155, Núm. 6, pp. 724-728

  2. Hair disorders in cancer survivors

    Journal of the American Academy of Dermatology, Vol. 80, Núm. 5, pp. 1199-1213

  3. Hair disorders in patients with cancer

    Journal of the American Academy of Dermatology, Vol. 80, Núm. 5, pp. 1179-1196

  4. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study

    Annals of Oncology, Vol. 30, Núm. 3, pp. 397-404

  5. Safety of 5α-reductase inhibitors and spironolactone in breast cancer patients receiving endocrine therapies

    Breast Cancer Research and Treatment, Vol. 174, Núm. 1, pp. 15-26

2018

  1. Endocrine therapy-induced alopecia in patients with breast cancer

    JAMA Dermatology, Vol. 154, Núm. 6, pp. 670-675

2017

  1. Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition

    Oncogene, Vol. 36, Núm. 19, pp. 2737-2749

2015

  1. The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies

    Nature Genetics, Vol. 47, Núm. 3, pp. 250-256